Discover 1,190 paid clinical trials in Dayton, Ohio. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,190
New
Interactive Roles of Cardiorespiratory Fitness and Adiposity on Glucose and Vascular Control After Physical Inactivity
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Location: Fairfield OH, Cincinnati OH, Indianapolis IN,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07222566
Phase 3, Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
for
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma,
Location: Fairfield OH, Cincinnati OH, Chicago IL, Niles IL,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07392892
Phase 2, Phase 3, Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
for
Urothelial Cancer, Urinary Bladder Neoplasms
Location: Fairfield OH, Fort Wayne IN, Royal Oak MI, New Lenox IL,
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All
Age: 18+
Code: NCT07566156
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
for
Non-Small Cell Lung Cancer
Location: Fairfield OH, Arlington VA, Philadelphia PA, Boston MA,
Sponsor: BicycleTx Limited
Sex: All
Age: 18+
Code: NCT06933329
Phase 2, Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
for
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic,